
|Articles|August 28, 2020
Novel Approaches to Metastatic HER2+ Breast Cancer
Author(s)OncLive Staff
Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD, on Tuesday, October 13, 2020 at 8:00 PM CDT.
Advertisement
Considerations in Metastatic HER2+ Breast Cancer
Tuesday, October 13, 2020
8:00 PM-9:30 PM CDT
Tuesday, October 13, 2020
8:00 PM-9:30 PM CDT
Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD.
Topics of discussion at this virtual event include:
- Review and evaluate data on recent therapeutic advances in metastatic HER2+ breast cancer
- Discuss clinical challenges and areas of uncertainty faced when selecting later lines of therapy for patients with metastatic HER2+ breast cancer
- Identify factors that influence treatment selection and planning for patients with metastatic HER2+ breast cancer
Speakers:
Debu Tripathy, MD
Professor and Chair,
Department of Breast Medical Oncology
UT MD Anderson Cancer Center
Houston, Texas
Professor and Chair,
Department of Breast Medical Oncology
UT MD Anderson Cancer Center
Houston, Texas
Michelina Cairo, MD
Texas Oncology
Houston, TX
United States
Texas Oncology
Houston, TX
United States
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5







































































